Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 09, 2026 07:00 ET | Source: SparingVision

SparingVision Successfully Completes PRODYGY Trial Patient Dosing with SPVN06, its Novel Neuroprotective Gene Therapy

All patients dosed with SPVN06 in Phase I/II trial continue to demonstrate a favorable safety profileInitial data readout for this novel gene-agnostic therapy expected in 2027 Paris, February 9,...
August 30, 2023 07:00 ET | Source: SparingVision

SparingVision Reports Positive Initial Safety Data from the first cohort treated in its PRODYGY Phase I/II Gene Therapy Trial

SparingVision Reports Positive Initial Safety Data from the first cohort treated in its PRODYGY Phase I/II Gene Therapy Trial Lead gene therapy asset, SPVN06, reported to be well-tolerated in first...